MedTrace Logo

A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects

NCT04135898 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2023-12-29

No results posted yet for this study

Summary

This is a randomised, double-blind, positive drug parallel controlled clinical trial in China. In the trial, it is planned to enroll 88 subjects, randomized to two treatment groups in a ratio of 1:1 to receive the test drug and the positive control.

Conditions

  • Healthy Male

Interventions

DRUG

SIBP-04

3mg/kg, infusion in 90 minutes

DRUG

Bevacizumab

3mg/kg, infusion in 90 minutes

Sponsors & Collaborators

  • Shanghai Institute Of Biological Products

    lead INDUSTRY

Principal Investigators

  • Shanghai Institute Of Biological Products Co., Ltd · SINOPHARM

  • The First Affiliated Hospital · Bengbu Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-23
Primary Completion
2020-03-16
Completion
2020-03-16

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04135898 on ClinicalTrials.gov